London
· Delayed Price · Currency is GBP · Price in USD 10x Genomics Statistics
Total Valuation
10x Genomics has a market cap or net worth of GBP 745.35 million. The enterprise value is 488.38 million.
| Market Cap | 745.35M |
| Enterprise Value | 488.38M |
Important Dates
The last earnings date was Friday, May 2, 2025.
| Earnings Date | May 2, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 111.09M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +2.66% |
| Shares Change (QoQ) | +0.83% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 109.32M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.54 |
| PB Ratio | 1.36 |
| P/TBV Ratio | 1.40 |
| P/FCF Ratio | 21.23 |
| P/OCF Ratio | 16.97 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -4.02 |
| EV / Sales | 1.06 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 13.91 |
Financial Position
The company has a current ratio of 5.37, with a Debt / Equity ratio of 0.11.
| Current Ratio | 5.37 |
| Quick Ratio | 4.44 |
| Debt / Equity | 0.11 |
| Debt / EBITDA | n/a |
| Debt / FCF | 1.77 |
| Interest Coverage | -60,528.88 |
Financial Efficiency
Return on equity (ROE) is -22.03% and return on invested capital (ROIC) is -14.20%.
| Return on Equity (ROE) | -22.03% |
| Return on Assets (ROA) | -12.43% |
| Return on Invested Capital (ROIC) | -14.20% |
| Return on Capital Employed (ROCE) | -22.83% |
| Revenue Per Employee | 370,201 |
| Profits Per Employee | -93,066 |
| Employee Count | 1,306 |
| Asset Turnover | 0.68 |
| Inventory Turnover | 2.50 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -66.70% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -66.70% |
| 50-Day Moving Average | 8.81 |
| 200-Day Moving Average | 14.68 |
| Relative Strength Index (RSI) | 42.19 |
| Average Volume (20 Days) | 2,751 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 4.34 |
Income Statement
In the last 12 months, 10x Genomics had revenue of GBP 483.48 million and -121.54 million in losses. Loss per share was -1.00.
| Revenue | 483.48M |
| Gross Profit | 330.50M |
| Operating Income | -140.55M |
| Pretax Income | -118.73M |
| Net Income | -121.54M |
| EBITDA | -113.69M |
| EBIT | -140.55M |
| Loss Per Share | -1.00 |
Balance Sheet
The company has 330.42 million in cash and 61.98 million in debt, giving a net cash position of 268.44 million.
| Cash & Cash Equivalents | 330.42M |
| Total Debt | 61.98M |
| Net Cash | 268.44M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 547.13M |
| Book Value Per Share | 4.44 |
| Working Capital | 365.19M |
Cash Flow
In the last 12 months, operating cash flow was 43.92 million and capital expenditures -8.80 million, giving a free cash flow of 35.11 million.
| Operating Cash Flow | 43.92M |
| Capital Expenditures | -8.80M |
| Free Cash Flow | 35.11M |
| FCF Per Share | n/a |
Margins
Gross margin is 68.36%, with operating and profit margins of -29.07% and -25.14%.
| Gross Margin | 68.36% |
| Operating Margin | -29.07% |
| Pretax Margin | -24.56% |
| Profit Margin | -25.14% |
| EBITDA Margin | -23.51% |
| EBIT Margin | -29.07% |
| FCF Margin | 7.26% |
Dividends & Yields
10x Genomics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.66% |
| Shareholder Yield | n/a |
| Earnings Yield | -16.31% |
| FCF Yield | 4.71% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
10x Genomics has an Altman Z-Score of 5.27.
| Altman Z-Score | 5.27 |
| Piotroski F-Score | n/a |